Auris Medical Provides Update on Intranasal Betahistine Development Program
April 03, 2020 17:00 ET
|
Auris Medical AG
Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full...
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
March 05, 2020 08:30 ET
|
Auris Medical AG
Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with...
Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model
February 25, 2020 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Notice of Allowance for European Patent Application
January 10, 2020 08:30 ET
|
Auris Medical AG
Received “Intention to Grant” notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
December 30, 2019 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
October 11, 2019 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
September 13, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
September 11, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Appointment of New Chief Financial Officer
September 04, 2019 07:00 ET
|
Auris Medical AG
Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
August 26, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...